Barrington analyst Michael Petusky lowered the firm’s price target on Merit Medical (MMSI) to $111 from $115 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company reported strong Q4, with record free cash flow, but full year 2025 earnings guidance was lighter than expected.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $116 from $122 at Needham
- Merit Medical price target lowered to $127 from $128 at Canaccord
- Strong Growth and Positive Outlook Drive Buy Rating for Merit Medical Systems Despite EPS Challenges
- Merit Medical price target lowered to $117 from $120 at Wells Fargo
- Strong Financial Performance and Strategic Execution Drive Buy Rating for Merit Medical Systems